These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20547804)

  • 1. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").
    Yang SJ; Xiong YQ; Boyle-Vavra S; Daum R; Jones T; Bayer AS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3161-9. PubMed ID: 20547804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
    Xiong YQ; Hady WA; Bayer AS; Chen L; Kreiswirth BN; Yang SJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5528-33. PubMed ID: 22890759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
    Yang SJ; Nast CC; Mishra NN; Yeaman MR; Fey PD; Bayer AS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3079-85. PubMed ID: 20498310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.
    Mehta S; Singh C; Plata KB; Chanda PK; Paul A; Riosa S; Rosato RR; Rosato AE
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6192-200. PubMed ID: 22985884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.
    Abdelhady W; Bayer AS; Gonzales R; Li L; Xiong YQ
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus:
    Mishra NN; Lew C; Abdelhady W; Lapitan CK; Proctor RA; Rose WE; Bayer AS
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164921. PubMed ID: 34694870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of
    Jiang S; Zhuang H; Zhu F; Wei X; Zhang J; Sun L; Ji S; Wang H; Wu D; Zhao F; Yan R; Yu Y; Chen Y
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0129521. PubMed ID: 34662187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.
    Renzoni A; Kelley WL; Rosato RR; Martinez MP; Roch M; Fatouraei M; Haeusser DP; Margolin W; Fenn S; Turner RD; Foster SJ; Rosato AE
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and genetic changes associated with the seesaw effect in MRSA strain N315 in a bioreactor model.
    Mishra S; Lasek-Nesselquist E; Mathur A; Ma Z; Boonthaworn K; O'Donnell N; Sui H; Pata JD; McDonough KA; Jayachandran P; Malik M
    J Glob Antimicrob Resist; 2022 Mar; 28():249-253. PubMed ID: 35085792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis.
    García-de-la-Mària C; Gasch O; García-Gonzalez J; Soy D; Shaw E; Ambrosioni J; Almela M; Pericàs JM; Tellez A; Falces C; Hernandez-Meneses M; Sandoval E; Quintana E; Vidal B; Tolosana JM; Fuster D; Llopis J; Pujol M; Moreno A; Marco F; Miró JM
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
    Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.
    Berti AD; Wergin JE; Girdaukas GG; Hetzel SJ; Sakoulas G; Rose WE
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5046-53. PubMed ID: 22802248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; Soy D; Moreno A; del Río A; Almela M; Sarasa M; Mestres CA; Gatell JM; Jiménez de Anta MT; Marco F;
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4172-7. PubMed ID: 19620326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis
    Mishra NN; Abdelhady W; Elsayed AM; Lapitan C; Proctor RA; Rybak MJ; Miro JM; Bayer AS
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0147222. PubMed ID: 36877026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Clinical Isolates Among Daptomycin-Naive Patients in Korea.
    Nam EY; Yang SJ; Kim ES; Cho JE; Park KH; Jung SI; Yoon N; Kim DM; Lee CS; Jang HC; Park Y; Lee KS; Kwak YG; Lee JH; Park SY; Hwang JH; Kim M; Song KH; Kim HB
    Microb Drug Resist; 2018 Jun; 24(5):534-541. PubMed ID: 29863982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.
    Mishra NN; Yang SJ; Chen L; Muller C; Saleh-Mghir A; Kuhn S; Peschel A; Yeaman MR; Nast CC; Kreiswirth BN; Crémieux AC; Bayer AS
    PLoS One; 2013; 8(8):e71151. PubMed ID: 23990934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.